Vaccine Therapy and Sargramostim Compared With Placebo and Sargramostim Following Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

Conditions

• Lymphoma

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• autologous immunoglobulin idiotype-KLH conjugate vaccine — BIOLOGICAL
• rituximab — BIOLOGICAL
• sargramostim — BIOLOGICAL

Study Details

RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Vaccines made from a person's cancer cells may make the body build an immune response to kill cancer cells. Colony-stimulating factors such as GM-CSF increase the number of immune cells found in bone marrow and peripheral blood. It is not yet known whether combining rituximab and GM-CSF with vaccine therapy may cause a stronger immune response and kill more cancer cells. PURPOSE: This randomized phase III trial is studying giving rituximab and GM-CSF together with vaccine therapy and comparing it to giving rituximab and GM-CSF alone in treating patients with newly diagnosed, relapsed, or refractory B-cell non-Hodgkin's lymphoma.

Key Dates

Start date

Jul 31, 2004

Status verified

Feb 2006

Study Design

Allocation

RANDOMIZED

Primary purpose

TREATMENT

Primary Outcome Measure

Time to progression after 248 patients have progressed

Locations (60)

Find similar trials in Birmingham, AL

Related Studies

• Bone Marrow Grafting for Leukemia and Lymphoma
  Enrolling By Invitation · Stanford University · Stanford, California
• Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
  Recruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey
• 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
  Recruiting · Barbara Ann Karmanos Cancer Institute · Detroit, Michigan
• Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
  Recruiting · UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina